ASCL3

Summary

ASCL3 (achaete-scute family bHLH transcription factor 3, HGNC:740) is a protein-coding gene on chromosome 11p15.4, encoding Achaete-scute homolog 3 (Q9NQ33). Transcriptional repressor.

Basic helix-loop-helix transcription factors, such as ASCL3, are essential for the determination of cell fate and the development and differentiation of numerous tissues (Jonsson et al., 2004 [PubMed 15475265]).

Source: NCBI Gene 56676 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 39 total
• GTEx eGene: eQTL in 2 tissues, sQTL in 0 (q < 0.05)
• Constraint (gnomAD): pLI 0.06 (LoF-tolerant), LOEUF 1.50 (unconstrained)
• MANE Select transcript: NM_020646

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:740
Approved symbol	ASCL3
Name	achaete-scute family bHLH transcription factor 3
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Aliases	bHLHa42, HASH3, Sgn1
Ensembl gene	ENSG00000176009
Ensembl biotype	protein_coding
OMIM	609154
Entrez	56676

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

MANE Select: ENST00000531618

ENST00000531618

RefSeq mRNA: 1 — MANE Select: NM_020646 NM_020646

CCDS: CCDS7795

Canonical transcript exons

ENST00000531618 — 2 exons

Exon	Start	End
ENSE00002200903	8937578	8938173
ENSE00003934416	8942986	8943016

Expression profiles

Bgee: expression breadth broad, 51 present calls, max score 76.33.

Highest expression (Bgee): olfactory segment of nasal mucosa, hair follicle, minor salivary gland, saliva-secreting gland, mouth mucosa.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ASCL3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 2 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

2 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	eqtl	1.2e-02	-1.11	11:9929837:A:G
Minor Salivary Gland	eqtl	3.2e-02	+0.29	11:8926510:C:T

Top tissues by expression

showing 100 of 189 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	76.33	gold quality
hair follicle	UBERON:0002073	72.99	gold quality
minor salivary gland	UBERON:0001830	70.77	gold quality
saliva-secreting gland	UBERON:0001044	69.76	gold quality
mouth mucosa	UBERON:0003729	67.11	gold quality
bone marrow cell	CL:0002092	65.83	gold quality
parotid gland	UBERON:0001831	63.60	gold quality
mucosa of paranasal sinus	UBERON:0005030	58.52	gold quality
nasal cavity mucosa	UBERON:0001826	57.61	gold quality
colonic epithelium	UBERON:0000397	57.05	gold quality
decidua	UBERON:0002450	56.55	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
sural nerve	UBERON:0015488	47.88	silver quality
cranial nerve II	UBERON:0000941	47.39	silver quality
periodontal ligament	UBERON:0008266	47.14	gold quality
renal glomerulus	UBERON:0000074	46.86	gold quality
metanephric glomerulus	UBERON:0004736	46.77	gold quality
nephron tubule	UBERON:0001231	46.71	gold quality
tonsil	UBERON:0002372	46.37	gold quality
bone marrow	UBERON:0002371	46.01	gold quality
nasal cavity epithelium	UBERON:0005384	45.90	silver quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	45.35	gold quality
inferior olivary complex	UBERON:0002127	45.14	gold quality
palpebral conjunctiva	UBERON:0001812	44.31	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
gingiva	UBERON:0001828	43.36	gold quality
renal medulla	UBERON:0000362	42.66	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
medulla oblongata	UBERON:0001896	42.39	gold quality
gingival epithelium	UBERON:0001949	42.19	gold quality
tongue	UBERON:0001723	42.12	gold quality
superior vestibular nucleus	UBERON:0007227	41.50	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
quadriceps femoris	UBERON:0001377	41.37	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
cortical plate	UBERON:0005343	41.33	gold quality
subthalamic nucleus	UBERON:0001906	40.90	gold quality
dorsal plus ventral thalamus	UBERON:0001897	40.88	gold quality
amniotic fluid	UBERON:0000173	40.69	gold quality
jejunal mucosa	UBERON:0000399	40.59	gold quality
biceps brachii	UBERON:0001507	40.57	gold quality
pigmented layer of retina	UBERON:0001782	40.50	gold quality
epithelium of nasopharynx	UBERON:0001951	40.45	gold quality
myocardium	UBERON:0002349	40.45	gold quality
germinal epithelium of ovary	UBERON:0001304	40.33	gold quality
esophagus squamous epithelium	UBERON:0006920	40.29	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	40.27	gold quality
jejunum	UBERON:0002115	40.18	gold quality
epithelium of mammary gland	UBERON:0003244	40.18	gold quality
cartilage tissue	UBERON:0002418	40.06	gold quality
oviduct epithelium	UBERON:0004804	40.03	gold quality
mammary duct	UBERON:0001765	39.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	39.95	gold quality
oral cavity	UBERON:0000167	39.86	gold quality
deltoid	UBERON:0001476	39.83	gold quality
saphenous vein	UBERON:0007318	39.83	gold quality
oocyte	CL:0000023	39.80	gold quality
urethra	UBERON:0000057	39.80	gold quality
heart right ventricle	UBERON:0002080	39.79	gold quality
pericardium	UBERON:0002407	39.77	gold quality
layer of synovial tissue	UBERON:0007616	39.77	gold quality
endothelial cell	CL:0000115	39.75	gold quality
synovial joint	UBERON:0002217	39.70	gold quality
dorsal root ganglion	UBERON:0000044	39.68	gold quality
nipple	UBERON:0002030	39.68	gold quality
penis	UBERON:0000989	39.64	gold quality
trigeminal ganglion	UBERON:0001675	39.63	gold quality
tendon of biceps brachii	UBERON:0008188	39.60	gold quality
inferior vagus X ganglion	UBERON:0005363	39.57	gold quality
superior surface of tongue	UBERON:0007371	39.56	gold quality
pylorus	UBERON:0001166	39.55	gold quality
muscle tissue	UBERON:0002385	39.54	silver quality
pons	UBERON:0000988	39.51	gold quality
thymus	UBERON:0002370	39.50	gold quality
cardia of stomach	UBERON:0001162	39.46	gold quality
colonic mucosa	UBERON:0000317	39.45	gold quality
parietal pleura	UBERON:0002400	39.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	39.40	gold quality
cerebellar vermis	UBERON:0004720	39.37	gold quality
ventral tegmental area	UBERON:0002691	39.35	gold quality
trachea	UBERON:0003126	39.33	gold quality
parietal lobe	UBERON:0001872	39.32	gold quality
vena cava	UBERON:0004087	39.31	gold quality
pharyngeal mucosa	UBERON:0000355	39.27	gold quality
substantia nigra pars compacta	UBERON:0001965	39.23	gold quality
visceral pleura	UBERON:0002401	39.23	gold quality
postcentral gyrus	UBERON:0002581	39.23	gold quality
body of tongue	UBERON:0011876	39.22	gold quality
medial globus pallidus	UBERON:0002477	39.18	gold quality
trabecular bone tissue	UBERON:0002483	39.18	gold quality
globus pallidus	UBERON:0001875	39.15	gold quality
substantia nigra pars reticulata	UBERON:0001966	39.11	gold quality
caecum	UBERON:0001153	39.05	gold quality
entorhinal cortex	UBERON:0002728	39.05	gold quality
lateral nuclear group of thalamus	UBERON:0002736	39.00	gold quality
corpus epididymis	UBERON:0004359	38.98	gold quality
tibia	UBERON:0000979	38.93	gold quality
lateral globus pallidus	UBERON:0002476	38.81	gold quality
urinary bladder	UBERON:0001255	38.77	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	12.12
E-ANND-3	no	1.63

HPA expression

RNA tissue specificity: Tissue enriched

showing 60 of 67 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Salivary gland	tissue	7.5	medium
Medulla oblongata	tissue	1.1
Choroid plexus	tissue	0.8
Spinal cord	tissue	0.8
Retrosplenial cortex	tissue	0.7
Hippocampus	tissue	0.6	low
Putamen	tissue	0.5
Nucleus accumbens	tissue	0.5
Substantia nigra	tissue	0.5
Locus coeruleus	tissue	0.5
Thymus	tissue	0.5
Cerebellum	tissue	0.4	low
Cerebral cortex	tissue	0.3	medium
Basal ganglia	tissue	0.3	low
Corpus callosum	tissue	0.3
Ventral forebrain	tissue	0.3
Somatosensory cortex	tissue	0.3
Retina	tissue	0.2
Pons	tissue	0.2
Frontal cortex	tissue	0.2
Thalamus	tissue	0.2
Hypothalamus	tissue	0.2
Retrosplenial and cingulate cortex	tissue	0.2
Caudate putamen	tissue	0.2
Cervix	tissue	0.1	medium
Testis	tissue	0.1	medium
Amygdala	tissue	0.1
Midbrain	tissue	0.1
Spleen	tissue	0.1	low
Duodenum	tissue	0.1	medium
Prostate	tissue	0.1	not detected
Tonsil	tissue	0.1	low
Postcentral gyrus	tissue	0.1
Entorhinal cortex	tissue	0.1
Olfactory bulb	tissue	0.1
Occipital cortex	tissue	0.1
Skin 1	tissue	0.0	medium
Lymph node	tissue	0.0	low
Breast	tissue	0.0	medium
Stomach 1	tissue	0.0	low
Heart muscle	tissue	0.0	low
Ovary	tissue	0.0	low
Vagina	tissue	0.0	medium
Seminal vesicle	tissue	0.0	low
Adipose tissue	tissue	0.0	low
Esophagus	tissue	0.0	medium
Rectum	tissue	0.0	low
Parathyroid gland	tissue	0.0	medium
Skeletal muscle	tissue	0.0	medium
Smooth muscle	tissue	0.0	low
Colon	tissue	0.0	low
Urinary bladder	tissue	0.0	low
Endometrium 1	tissue	0.0	medium
Epididymis	tissue	0.0	medium
Thyroid gland	tissue	0.0	medium
Lung	tissue	0.0	low
Small intestine	tissue	0.0	low
Gallbladder	tissue	0.0	medium
Kidney	tissue	0.0	medium
Adrenal gland	tissue	0.0	medium

Brain sub-regions (HPA Brain Atlas): detected in 187; highest nTPM — Flocculonodular lobe (1.3), Vermis (1.3), Cerebellar cortex (1.1), Nucleus gracilis (1.1), Area postrema (1.0).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets:

Target	Regulation
CD74
ERVW-4

Functional genomics

gnomAD constraint: pLI 0.0567, LOEUF 1.5, missense Z -0.0424 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000531618 — one region, missense o/e 1.06.

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ascl1a	ENSDARG00000038386
mus_musculus	Ascl3	ENSMUSG00000035951
rattus_norvegicus	Ascl3	ENSRNOG00000013591
drosophila_melanogaster	ac	FBGN0000022
drosophila_melanogaster	ase	FBGN0000137

Paralogs (4): ASCL1 (ENSG00000139352), ASCL2 (ENSG00000183734), ASCL4 (ENSG00000187855), ASCL5 (ENSG00000232237)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Xenopus laevis	Q06234	88.4%	Diamond
Gallus gallus	P24899	80.3%	Diamond
Bos taurus	Q2EGB9	78.8%	Diamond
Caenorhabditis elegans	Q18590	71.8%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
DENND2B-AS1	ncRNA	102724784
AKIP1	protein-coding	56672
C11orf16	protein-coding	56673
DENND2B	protein-coding	6764
MIR5691	ncRNA	100847015
TMEM9B-AS1	ncRNA	493900
TMEM9B	protein-coding	56674
NRIP3	protein-coding	56675
SCUBE2	protein-coding	57758
NRIP3-DT	ncRNA	105376541
RPL27A	protein-coding	6157
SNORA3A	snoRNA	619562
SNORA3B	snoRNA	677826

Protein

Protein identifiers

Achaete-scute homolog 3 — Q9NQ33 (reviewed: Q9NQ33)

Alternative names: Class A basic helix-loop-helix protein 42, bHLH transcriptional regulator Sgn-1

All UniProt accessions (1): Q9NQ33

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor. Inhibits myogenesis. Plays a role in progenitor cells which differentiate into ductal and acinar, but not myoepithelial, cell lineages in the salivary glands. Involved in the functions of the microvillar cells and Bowman’s glands and probably, in a non-cell-autonomous manner, in the development or regeneration of a complete olfactory epithelium (OE).

Subunit / interactions. Efficient DNA binding requires dimerization with another bHLH protein.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed in fetal and adult tissues.

RefSeq proteins (1): NP_065697* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011598	bHLH_dom	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR050283	E-box_TF_Regulators	Family

Pfam: PF00010

UniProt features (5 total): region of interest 2, chain 1, domain 1, sequence variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQ33-F1	69.74	0.31

Human Protein Atlas

Protein class: Predicted intracellular proteins, Transcription factors, Basic domains

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH uncertain

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 82 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_SALIVARY_GLAND_DEVELOPMENT, GOBP_GROWTH, GOBP_REGENERATION, NFKB_Q6, NFKB_C, GOBP_EXOCRINE_SYSTEM_DEVELOPMENT, OCT1_06, GOBP_TISSUE_REGENERATION, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, IK3_01, OCT1_B, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, GOBP_HOMEOSTATIC_PROCESS

GO Biological Process (9): tissue homeostasis (GO:0001894), DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), salivary gland development (GO:0007431), positive regulation of transcription by RNA polymerase II (GO:0045944), sensory epithelium regeneration (GO:0070654), negative regulation of transcription by RNA polymerase II (GO:0000122), animal organ development (GO:0048513), epithelium development (GO:0060429)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA binding (GO:0003677), protein dimerization activity (GO:0046983), protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), RNA polymerase II transcription regulator complex (GO:0090575), nucleus (GO:0005634), transcription regulator complex (GO:0005667)

GO top-level categories

30 GO namespaces:

Category	Terms
transcription by RNA polymerase II	3
regulation of transcription by RNA polymerase II	3
animal gross anatomical part developmental process	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
multicellular organismal-level homeostasis	1
anatomical structure homeostasis	1
gene expression	1
RNA biosynthetic process	1
regulation of DNA-templated transcription	1
exocrine system development	1
gland development	1
positive regulation of DNA-templated transcription	1
epithelium regeneration	1
negative regulation of DNA-templated transcription	1
tissue development	1
transcription cis-regulatory region binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
nucleic acid binding	1
protein binding	1
binding	1
chromosome	1
cellular anatomical structure	1
transcription regulator complex	1
nuclear protein-containing complex	1
intracellular membrane-bounded organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

showing 15 of 398 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ASCL3	FOXI1	Q12951	713
ASCL3	ACSL3	O95573	592
ASCL3	CFTR	P13569	577
ASCL3	MYOD1	P15172	550
ASCL3	TRPM5	Q9NZQ8	548
ASCL3	DRC12	Q494R4	502
ASCL3	ACSL4	O60488	454
ASCL3	KRT5	P13647	446
ASCL3	COPS7A	Q9UBW8	441
ASCL3	LYPD2	Q6UXB3	423
ASCL3	CFAP263	Q9H0I3	422
ASCL3	AQP5	P55064	386
ASCL3	BSCL2	Q96G97	370
ASCL3	BANP	Q8N9N5	370
ASCL3	GPAT4	Q86UL3	370

IntAct

Human interaction partners of ASCL3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
TCF4	physical association	0.560	4
HEMK1	physical association	0.560	3
ID1	physical association	0.560	3
TCF12	physical association	0.560	3
TCF3	physical association	0.560	3
VPS37C	physical association	0.560	3

BioGRID (19 interactions; top human partners by supporting records): TCF4 (Two-hybrid; 3 records), TCF12 (Two-hybrid; 2 records), TCF3 (Two-hybrid; 2 records), ADIPOR2 (Affinity Capture-MS), APP (Reconstituted Complex), C2orf49 (Affinity Capture-MS), HEMK1 (Two-hybrid), ID1 (Two-hybrid), ID4 (Affinity Capture-MS), SPPL3 (Positive Genetic), VPS37C (Two-hybrid)

Disease & clinical

Genetic variants

Variant evidence for ASCL3: 39 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	2
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 17 predictions of 62):

Position(s)	Effect	Δscore	Sites
11:8942984–8942985	donor_loss	0.9900	3
11:8942985	donor_loss	0.9800
11:8938174–8938175	acceptor_loss	0.9700	6
11:8942985	donor_loss	0.9700
11:8937932	acceptor_gain	0.9500
11:8938176	acceptor_loss	0.9200
11:8938182	acceptor_loss	0.9200
11:8941290	acceptor_gain	0.8100
11:8938182	acceptor_loss	0.7300
11:8941234	donor_gain	0.7000

HPA cancer prognostics

RNA cancer specificity: Group enriched (Bladder Urothelial Carcinoma, Kidney Chromophobe)

Disease associations

OMIM: gene MIM:609154 | disease phenotypes:

GWAS associations

4 associations:

Study	Trait	p-value
GCST005953_4	Body mass index (age <50)	4e-11
GCST005950_10	Body mass index x sex x age interaction (4df test)	6e-11
GCST005951_61	Body mass index	8e-11
GCST010703_321	Brain morphology (MOSTest)	5e-9

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Coal	increases abundance, increases expression	1
Methotrexate	decreases expression	1
Smoke	increases abundance, increases expression	1
Tobacco Smoke Pollution	decreases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00117546	Phase 4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	Phase 4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	Phase 4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	Phase 4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	Phase 4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	Phase 4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	Phase 4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	Phase 4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	Phase 4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	Phase 4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	Phase 4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	Phase 4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	Phase 4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	Phase 4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	Phase 4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	Phase 4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	Phase 4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	Phase 4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	Phase 4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	Phase 4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	Phase 4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	Phase 4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	Phase 4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	Phase 4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	Phase 4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	Phase 4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	Phase 4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	Phase 4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	Phase 4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	Phase 4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	Phase 4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	Phase 4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	Phase 4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	Phase 4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	Phase 4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	Phase 4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	Phase 4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	Phase 4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	Phase 4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	Phase 4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial
NCT06359015	Phase 4	TERMINATED	Metformin and Esomeprazole in Preterm Pre-eclampsia
NCT06468202	Phase 4	RECRUITING	Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT06632379	Phase 4	RECRUITING	AtorvaStatin Postpartum and Reduction of Cardiovascular risK
NCT06785116	Phase 4	RECRUITING	A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
NCT07167862	Phase 4	NOT_YET_RECRUITING	Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
NCT07288801	Phase 4	RECRUITING	Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women
NCT07293728	Phase 4	NOT_YET_RECRUITING	A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
NCT07361679	Phase 4	RECRUITING	LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
NCT07448597	Phase 4	RECRUITING	Progesterone Preeclampsia
NCT07510568	Phase 4	NOT_YET_RECRUITING	Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes
NCT07717931	Phase 4	COMPLETED	Vitamin D Therapy to Prevent Recurrent Preeclampsia in High-Risk Pregnancies
NCT07779057	Phase 4	RECRUITING	Comparison of High- Versus Low-Dose Aspirin for Pregnancy Outcomes in Women at High Risk of Preeclampsia
NCT07793760	Phase 4	NOT_YET_RECRUITING	Dexamethasone Versus Ondansetron for Preventing Post-Spinal Hypotension in Preeclampsia
NCT00000534	Phase 3	COMPLETED	Calcium for Pre-Eclampsia Prevention (CPEP)
NCT00097110	Phase 3	COMPLETED	RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil
NCT00135707	Phase 3	COMPLETED	Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
NCT00157521	Phase 3	COMPLETED	L-Arginine in Pre-Eclampsia
NCT00197340	Phase 3	COMPLETED	Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction
NCT00300937	Phase 3	COMPLETED	Coenzyme Q10 Supplementation and Development of Preeclampsia
NCT00848679	Phase 3	WITHDRAWN	Investigating the Novel Observation of Right-left Difference in Uterine Artery Vascular Resistance in Pre-eclampsia